Biosysen (HKSE:01355) Other Stockholders Equity: HK$10.71 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01355 Biosysen Ltd HKSE:01355
14 GF Score
Price HK$0.16
GF Value HK$0.06
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Biosysen Other Stockholders Equity?

Biosysen HKSE:01355 14 Other Stockholders Equity is HK$10.71 Mil as of Dec. 2025. GuruFocus rates HKSE:01355 with a GF Score™ of 14/100 and a GF Value™ of HK$0.06 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Biosysen's Other Stockholders Equity for the quarter that ended in Dec. 2025 was HK$10.71 Mil.

Biosysen's quarterly Other Stockholders Equity declined from Dec. 2024 (HK$11.53 Mil) to Jun. 2025 (HK$10.96 Mil) and declined from Jun. 2025 (HK$10.96 Mil) to Dec. 2025 (HK$10.71 Mil).

Biosysen's annual Other Stockholders Equity increased from Dec. 2023 (HK$11.40 Mil) to Dec. 2024 (HK$11.53 Mil) but then declined from Dec. 2024 (HK$11.53 Mil) to Dec. 2025 (HK$10.71 Mil).

Biosysen Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Biosysen's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biosysen Other Stockholders Equity Chart

Biosysen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.10 11.75 11.40 11.53 10.71

Biosysen Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.40 11.86 11.53 10.96 10.71
HKSE:01355
14GF Score
Biosysen Ltd HKSE:01355
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biosysen Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of HK$10.71 Mil mean?
Biosysen (HKSE:01355) has a Other Stockholders Equity of HK$10.71 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biosysen and its competitors.
Is Biosysen's Other Stockholders Equity too high?
Biosysen's current Other Stockholders Equity is HK$10.71 Mil. Overall, Biosysen has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosysen's Other Stockholders Equity compare to MAR and HLT?
Biosysen's Other Stockholders Equity of HK$10.71 Mil can be compared against companies in the Travel & Leisure industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Travel & Leisure company?
A good Other Stockholders Equity depends on the Travel & Leisure industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biosysen and its competitors. Biosysen's current Other Stockholders Equity is HK$10.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosysen stock overvalued right now?
Based on GuruFocus' analysis, Biosysen (HKSE:01355) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.16 — trading 173.3% above its estimated fair value. The current Other Stockholders Equity is HK$10.71 Mil. Biosysen's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Biosysen (HKSE:01355), the current Other Stockholders Equity is HK$10.71 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biosysen (HKSE:01355) Overvalued in 2026?

Based on GuruFocus' analysis, Biosysen stock appears to be overvalued. The current stock price of HK$0.16 is trading 173.3% above its estimated GF Value™ of HK$0.06. GuruFocus considers Biosysen to be Significantly Overvalued.

Key valuation signals for HKSE:01355:

  • Other Stockholders Equity: HK$10.71 Mil
  • GF Value™: HK$0.06 vs. price of HK$0.16 (173.3% above fair value)
  • GF Score™: 14/100 with 9 warning signs

No single metric tells the full story. See the HKSE:01355 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biosysen Business Description

Address 28 Yun Ping Road, Level 28, Lee Garden Two, Causeway Bay, Hong Kong, HKG
Biosysen Ltd is engaged in the accommodation operations and provision of accommodation consultations and accommodation facilities management services, and other related businesses in the People's Republic of China. It has two operating segments: the Accommodation business and the Healthcare and Beauty business. It generates the majority of its revenue from the Accommodation business. Geographically, it generates all of its revenue from the PRC.
14GF Score

Get the complete analysis for HKSE:01355

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.16
Price
HK$0.06
GF Value